Eli Lilly Drops Glenmark In $500M ADHD Drug Suit

Law360, New York (July 3, 2008, 12:00 AM EDT) -- Eli Lilly and Co. agreed to drop patent infringement charges against generics maker Glenmark Pharmaceuticals Inc. USA as long as Glenmark adheres to any future rulings regarding a generic version of Strattera, an Eli Lilly drug used to treat attention deficit hyperactivity disorder.

The consent judgment, handed down Tuesday in the U.S. District Court for the District of New Jersey, is the second agreement in a patent suit filed by Eli Lilly against 10 generics makers last September over the atomoxetine hydrochloride formulation.

Thursday's agreement barred...
To view the full article, register now.